TOR · —

Fennec Pharmaceuticals Inc. (FRX.TO) Stock

$15.28 +10.32% TOR: FRX.TO —

Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development.

Valuation

MetricValue
Price$15.28
Market Cap—
P/E Ratio—
P/B Ratio—
P/S Ratio—
EPS (TTM)—
52-Week High$16.10
52-Week Low$7.59
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin—
Operating Margin—
Net Margin—
Debt/Equity—
Current Ratio—

Latest News

Update: Cardinal Infrastructure Q2 Revenue Rises; 2026 Revenue Guidance Boosted MT Newswires · Aug 11, 2026 Citigroup Upgrades Evolent Health to Buy From Neutral, Adjusts PT to $6 From $6.75 MT Newswires · Aug 11, 2026 Citigroup Upgrades Everpure to Buy From Neutral, Adjusts PT to $118 From $90 MT Newswires · Aug 11, 2026 Citigroup Upgrades Agilon Health to Neutral From Sell, Adjusts Price Target to $115 From $105 MT Newswires · Aug 11, 2026 BTIG Downgrades Sionna Therapeutics to Neutral From Buy MT Newswires · Aug 11, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y34.04%
Return 3Y43.74%
Return 5Y69.40%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CYBN.NECybin Inc. — — — — 0.00%
DR.TOMedical Facilities Corporation $15.15 -13.23% — — 0.00%
EPRX.TOEupraxia Pharmaceuticals Inc. $9.37 +4.34% — — 0.00%
HBP.TOHelix BioPharma Corp. $1.66 +10.67% — — 0.00%
HITI.VHigh Tide Inc. $3.23 +8.75% — — 0.00%

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. is led by CEO Jeffrey S. Hackman, employs 35 people, headquartered in Research Triangle Park, US, publicly traded since 2001.

over the past 52 weeks the stock has ranged between $7.59 and $16.10, and currently trades 5.1% below its 52-week high.

Official website: www.fennecpharma.com

Related — Stocks

BNY — $152.52 -2.54% CIEN — $412.39 +2.14% CBRS — $188.61 -5.28% HEI.A AIRCRAFT ENGINES & ENGINE PARTS $216.35 +0.00% LEN.B GENERAL BLDG CONTRACTORS - RESIDENTIAL BLDGS $80.32 +0.00% WSO.B WHOLESALE-HARDWARE & PLUMBING & HEATING EQUIPMENT & SUPPLIES $453.37 +0.00% MKC.V MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS $51.78 +0.00% MOG.B MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $322.00 +0.00% MOG.A MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT $307.91 +0.00% UHAL.B SERVICES-AUTO RENTAL & LEASING (NO DRIVERS) $45.71 +0.00% TAP.A MALT BEVERAGES $47.89 +0.00% VSXY — $88.68 +0.50%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides